NicOx S.A. (Eurolist: COX) today announced the presentation of promising preclinical results from its August 2004 collaboration agreement with Pfizer Inc (NYSE: PFE), which is focused on the research and development of nitric oxide-donating derivatives of latanoprost for the treatment of glaucoma. The nitric oxide- donating compound was shown to have an improved ability to lower Intraocular Pressure (IOP) in validated preclinical models when compared to Pfizer’s latanoprost, the leader in world wide glaucoma sales, with approximately $1.5 billion of franchise sales in 2006 (see NOTE). These preclinical results were presented on Saturday, February 10, at the Association for Ocular Pharmacology and Therapeutics 8th Scientific Meeting in San Diego (United States).
